This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

03 Mar 2023

OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI award from the NHS AI Lab (joint unit of teams from the Department of Health and Social Care and NHS England and NHS Improvement). Fundings will be deployed to support a large UK clinical trial aimed at evaluating the clinical utility of the company’s OncoProg® test, a digital pathology solution that uses a sophisticated image... Read more

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

02 Feb 2023

- EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - - Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor - - Eligible for pre-commercial milestone payments and, if approved, tiered royalties on net product sales - OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a... Read more

BERGENBIO ANNOUNCES THE ESTABLISHMENT OF ONCOLOGY SCIENTIFIC ADVISORY BOARD

BERGENBIO ANNOUNCES THE ESTABLISHMENT OF ONCOLOGY SCIENTIFIC ADVISORY BOARD

02 Feb 2023

– Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC –  BERGEN, Norway, February 2, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer (NSCLC) experts from top oncology... Read more

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

01 Feb 2023

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica’s... Read more

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

01 Feb 2023

Scancell Holdings Plc (“Scancell” or the “Company”) Directorate Change Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board Jean-Michel brings 25 years of experience in the international pharmaceutical and biotech industries both in an executive and non-executive capacity Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More